Abstract:Background: Melanoma antigen gene (MAGE)-type antigens are promising targets for cancer immunotherapy as they are expressed in cancer cells but not in normal tissues, except for male germline cells. The mouse P1A antigen shares this MAGE-type expression pattern and has been used as a target antigen in preclinical tumor models aiming to induce antitumor CD8+ T-cell responses. However, so far only one MHC I-restricted P1A epitope has been identified. It is presented by H-2Ld in mice of the H-2d genetic background such as DBA/2 and BALB/c. Given the availability of multiple genetically altered strains of mice in the C57BL/6 background, it would be useful to define P1A T-cell epitopes presented by the H-2b haplotype, to facilitate more refined mechanistic studies. Methods: We employed a heterologous prime-boost vaccination strategy based on a chimpanzee adenovirus (ChAdOx1) and a modified vaccinia Ankara (MVA) encoding P1A, to induce P1A-specific T-cell responses in C57BL/6 mice. Vaccine-induced responses were measured by intracellular cytokine staining and multiparameter flow cytometry. We mapped the immunogenic CD8 epitope and cloned the cognate T-cell receptor (TCR), which we used for adoptive cell therapy. Results: ChAdOx1/MVA-P1A vaccination induces a strong P1A-specific CD8+ T-cell response in C57BL/6 mice. This response is directed against a single 9-amino acid peptide with sequence FAVVTTSFL, corresponding to P1A amino acids 43-51. It is presented by H-2Db. P1A vaccination, especially with ChAdOx1 administered intramuscularly and MVA delivered intravenously, protected mice against P1A-expressing EL4 (EL4.P1A) tumor cell challenge. We identified and cloned four TCRs that are specific for the H-2Db-restricted P1A43-51 peptide. T cells transduced with these TCRs recognized EL4.P1A but not MC38.P1A and B16F10.P1A tumor cells, likely due to differences in the proteasome subtypes present in these cells. Adoptive transfer of these T cells in mice bearing EL4.P1A tumors reduced tumor growth and increased survival. Conclusions: We identified the first CD8+ T-cell epitope of the MAGE-type P1A tumor antigen presented in the H-2b background. This opens new perspectives for mechanistic studies dissecting MAGE-type specific antitumor immunity, making use of the wealth of genetically altered mouse strains available in the C57BL/6 background. This should facilitate the advancement of specific cancer immunotherapies.

Identification Of A Novel Tumor Antigen That Resembles Mouse Tumor Rejection Antigen Pia

Preparation and Identification of Monoclonal Antibody Against Human Testis Development Related Gene 1

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

T351 Protein, a Novel Tumor Associated Antigen and Potential Target for Immunotherapy

On The Role Of Unmutated Antigens In Tumor Rejection In Mice With Unperturbed T-Cell Repertoires

Transgenic Expression of P1a Induced Thymic Tumor: A Role for Onco-Fetal Antigens in Tumorigenesis

Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.

Transduction of the Gene Coding for A Human G-Protein Coupled Receptor Fprl1 in Mouse Tumor Cells Increases Host Anti-Tumor Immunity

Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

[Expression and Characterization of Mouse 17-1A Antigen from Pichia Pastoris].

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies

Identification Of Special At-Rich Sequence Binding Protein 1 As A Novel Tumor Antigen Recognized By Cd8(+) T Cells: Implication For Cancer Immunotherapy

485 TIGIT/PVRIG Humanized Mice-an Idea Model for Studying Anti-Pvrig Antibodies

A Humanized Mouse Model for Generation of Tumor Antigen Specific T Cells for Preclinical Research and Anticancer Therapy (75.4)

Targeting Activation Induced Cytidine Deaminase Promotes Rejection of Large Established Tumors by Cytotoxic T Lymphocytes in a Mouse Myeloma Model

Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy

On the Site and Mode of Antigen Presentation for the Initiation of Clonal Expansion of CD8 T Cells Specific for a Natural Tumor Antigen.

Epitope identification for p53R273C mutant

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations

A novel putative tumor associated antigen